47% effective CureVac coronavirus vaccine project misses target | Serum

Notice, The lab acknowledged that the CureVac vaccine “does not meet the statistical criteria for success”. However, it has shown good levels of security. The analysis included nearly 40,000 participants in Latin America and Europe.

World Health Organization (Who is the) she has Suggest a minimum efficacy of 50% Covid-19 vaccines to be adopted. This is the case for all immunization devices licensed for emergency use in Brazil and currently in force in the country: Coronavac, AstraZeneca e Pfizer/BioNTech.

According to study officials, most cases of Covid-19 seen in volunteers who received two doses of the potential vaccine (not a placebo) were caused by Worrying variants of SARS-CoV-2 coronavirus.

“This variable-rich environment demonstrates the importance of developing a new generation of vaccines, as new types of virus continue to emerge,” warns Franz Werner Haas, CEO of CureVac.

Also, according to a statement, CureVac will continue future research with pharmaceutical company GSK in search of a second-generation vaccine, which will be included in vaccine schedules against Covid next year.

Use the CureVac Vaccine Project Extension messenger RNA (mRNA) technology, similar to those produced by Pfizer/BioNTech Laboratories and Moderna. However, it is worth noting that these two inhibitors have shown high efficacy against Covid-19 and helped suppress the epidemic. In countries such as Israel, the United States and the United Kingdom.

Learn how this technique works in the video below